Journal
HUMAN PATHOLOGY
Volume 38, Issue 1, Pages 185-189Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2006.07.014
Keywords
pathology; pituitary; pituitary neoplasms; prolactin; temozolomide
Categories
Ask authors/readers for more resources
Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Histologic, immunohistochemical, and electron microscopic study demonstrated marked morphological differences in the tumor exposed to temozolomide compared with the unexposed tumor. Necrosis, hemorrhagic areas, accumulation of connective tissue, focal inflammatory infiltration, and neuronal transformation were seen. Immunohistochemical prognostic indicators showed a reduction in growth potential. Based on the clinical, laboratory, and morphological findings, we recommend temozolomide therapy in patients with pituitary tumors not responding adequately to other treatment options. (c) 2007 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available